Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients

Ravi Rajaram; Arlene M. Correa; Ting Xu; Quynh Nhu Nguyen; Mara B. Antonoff; David Rice; Reza Mehran; Jack Roth; Garrett Walsh; Stephen Swisher; Wayne L. Hofstetter; Ara Vaporciyan; Tina Cascone; Anne S. Tsao; Vassiliki A. Papadimitrakopoulou; Saumil Gandhi; Zhongxing Liao; Boris Sepesi

doi:10.1016/j.cllc.2020.01.009

Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients

Ravi Rajaram, Arlene M. Correa, Ting Xu, Quynh Nhu Nguyen, Mara B. Antonoff, David Rice, Reza Mehran, Jack Roth, Garrett Walsh, Stephen Swisher, Wayne L. Hofstetter, Ara Vaporciyan, Tina Cascone, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Saumil Gandhi, Zhongxing Liao, Boris Sepesi

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Stage IIIA (N2) non–small-cell lung cancer patients undergoing surgery after neoadjuvant chemotherapy had locoregional recurrence of 15.1% compared to 30.3% in those completing definitive chemoradiation. At 5 years, overall survival (OS) was 50.8% and disease-free survival (DFS) was 33.1% in resected patients, whereas in unresected patients OS and DFS were 29.2% and 20.5%, respectively. Surgery may continue to play a role in well-selected stage IIIA (N2) patients.

Original language	English (US)
Pages (from-to)	e294-e301
Journal	Clinical Lung Cancer
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/j.cllc.2020.01.009
State	Published - Jul 2020

Keywords

Chemoradiation
Lobectomy
Outcomes research
Recurrence
Surgery

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2020.01.009

Cite this

Rajaram, R., Correa, A. M., Xu, T., Nguyen, Q. N., Antonoff, M. B., Rice, D., Mehran, R., Roth, J., Walsh, G., Swisher, S., Hofstetter, W. L., Vaporciyan, A., Cascone, T., Tsao, A. S., Papadimitrakopoulou, V. A., Gandhi, S., Liao, Z., & Sepesi, B. (2020). Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clinical Lung Cancer, 21(4), e294-e301. https://doi.org/10.1016/j.cllc.2020.01.009

Rajaram, R , Correa, AM , Xu, T , Nguyen, QN , Antonoff, MB , Rice, D , Mehran, R, Roth, J, Walsh, G , Swisher, S , Hofstetter, WL , Vaporciyan, A , Cascone, T , Tsao, AS, Papadimitrakopoulou, VA, Gandhi, S , Liao, Z & Sepesi, B 2020, 'Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients', Clinical Lung Cancer, vol. 21, no. 4, pp. e294-e301. https://doi.org/10.1016/j.cllc.2020.01.009

@article{cb55c92845334c0fa5aae5b45ea50163,

title = "Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients",

abstract = "Stage IIIA (N2) non–small-cell lung cancer patients undergoing surgery after neoadjuvant chemotherapy had locoregional recurrence of 15.1% compared to 30.3% in those completing definitive chemoradiation. At 5 years, overall survival (OS) was 50.8% and disease-free survival (DFS) was 33.1% in resected patients, whereas in unresected patients OS and DFS were 29.2% and 20.5%, respectively. Surgery may continue to play a role in well-selected stage IIIA (N2) patients.",

keywords = "Chemoradiation, Lobectomy, Outcomes research, Recurrence, Surgery",

author = "Ravi Rajaram and Correa, {Arlene M.} and Ting Xu and Nguyen, {Quynh Nhu} and Antonoff, {Mara B.} and David Rice and Reza Mehran and Jack Roth and Garrett Walsh and Stephen Swisher and Hofstetter, {Wayne L.} and Ara Vaporciyan and Tina Cascone and Tsao, {Anne S.} and Papadimitrakopoulou, {Vassiliki A.} and Saumil Gandhi and Zhongxing Liao and Boris Sepesi",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = jul,

doi = "10.1016/j.cllc.2020.01.009",

language = "English (US)",

volume = "21",

pages = "e294--e301",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer

T2 - Analysis of Resected and Unresected Patients

AU - Rajaram, Ravi

AU - Correa, Arlene M.

AU - Xu, Ting

AU - Nguyen, Quynh Nhu

AU - Antonoff, Mara B.

AU - Rice, David

AU - Mehran, Reza

AU - Roth, Jack

AU - Walsh, Garrett

AU - Swisher, Stephen

AU - Hofstetter, Wayne L.

AU - Vaporciyan, Ara

AU - Cascone, Tina

AU - Tsao, Anne S.

AU - Papadimitrakopoulou, Vassiliki A.

AU - Gandhi, Saumil

AU - Liao, Zhongxing

AU - Sepesi, Boris

PY - 2020/7

Y1 - 2020/7

N2 - Stage IIIA (N2) non–small-cell lung cancer patients undergoing surgery after neoadjuvant chemotherapy had locoregional recurrence of 15.1% compared to 30.3% in those completing definitive chemoradiation. At 5 years, overall survival (OS) was 50.8% and disease-free survival (DFS) was 33.1% in resected patients, whereas in unresected patients OS and DFS were 29.2% and 20.5%, respectively. Surgery may continue to play a role in well-selected stage IIIA (N2) patients.

AB - Stage IIIA (N2) non–small-cell lung cancer patients undergoing surgery after neoadjuvant chemotherapy had locoregional recurrence of 15.1% compared to 30.3% in those completing definitive chemoradiation. At 5 years, overall survival (OS) was 50.8% and disease-free survival (DFS) was 33.1% in resected patients, whereas in unresected patients OS and DFS were 29.2% and 20.5%, respectively. Surgery may continue to play a role in well-selected stage IIIA (N2) patients.

KW - Chemoradiation

KW - Lobectomy

KW - Outcomes research

KW - Recurrence

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85079839520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079839520&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.01.009

DO - 10.1016/j.cllc.2020.01.009

M3 - Article

C2 - 32089476

AN - SCOPUS:85079839520

SN - 1525-7304

VL - 21

SP - e294-e301

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 4

ER -

Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this